Gut · 2024 · 12 citations · 32 references
Life SciencesImmunologyOncologyImmunotherapyTumor ImmunologyTumor MicroenvironmentCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint ModulationTumor Immune SurveillanceTumor Microenvironment ModulationCheckpoint Blockade ModulationCrispr-cas9 KnockoutEpigenetic DysregulationEpigenetic Gene SilencingEpigenetic SilencingImmune Checkpoint Inhibitor TherapyResistance Mechanisms To ImmunotherapyResistance To Checkpoint Inhibitors
Objective Pancreatic ductal adenocarcinoma (PDAC) stands as one of the most lethal cancers, marked by its lethality and limited treatment options, including the utilisation of checkpoint blockade (ICB) immunotherapy. Epigenetic dysregulation is a defining feature of tumourigenesis that is implicated in immune surveillance, but remains elusive in PDAC. Design To identify the factors that modulate immune surveillance, we employed in vivo epigenetic-focused CRISPR-Cas9 screen in mouse PDAC tumour models engrafted in either immunocompetent or immunodeficient mice. Results Here, we identified MED12 as a top hit, emerging as a potent negative modulator of immune tumour microenviroment (TME) in PDAC. Loss of Med12 significantly promoted infiltration and cytotoxicity of immune cells including CD8 + T cells, natural killer (NK) and NK1.1 + T cells in tumours, thereby heightening the sensitivity of ICB treatment in a mouse model of PDAC. Mechanistically, MED12 stabilised heterochromatin protein HP1A to repress H3K9me3-marked endogenous retroelements. The derepression of retrotransposons induced by MED12 loss triggered cytosolic nucleic acid sensing and subsequent activation of type I interferon pathways, ultimately leading to robust inflamed TME . Moreover, we uncovered a negative correlation between MED12 expression and immune resposne pathways, retrotransposon levels as well as the prognosis of patients with PDAC undergoing ICB therapy. Conclusion In summary, our findings underscore the pivotal role of MED12 in remodelling immnue TME through the epigenetic silencing of retrotransposons, offering a potential therapeutic target for enhancing tumour immunogenicity and overcoming immunotherapy resistance in PDAC.
32
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley et al. · Nature · 2014 · 6.6K citations · Full text
Life Sciences, Immunology, Pathology +14
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter J. Bailey, David K. Chang, Kátia Nones et al. · Nature · 2016 · 3.7K citations
Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain
Andrew J. Bannister, Philip Zegerman, Janet F. Partridge et al. · Nature · 2001 · 2.9K citations
Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins
Monika Lachner, Dónal O’Carroll, Stephen Rea et al. · Nature · 2001 · 2.8K citations
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
Benjamin J. Raphael, Ralph H. Hruban, Andrew J. Aguirre et al. · Cancer Cell · 2017 · 2.1K citations · Full text